Claims for Patent: 8,895,033

Summary for Patent: 8,895,033

Title:	Sustained release formulations using non-aqueous carriers
Abstract:	The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.
Inventor(s):	Houchin; Mary L. (Rockville, MD), Lee; Robin H. (San Diego, CA), Qi; Hong (San Diego, CA), Oehrtman; Greg (San Diego, CA), Jennings; Robert N. (San Diego, CA), Coleman; Scott H. (San Diego, CA)
Assignee:	Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)
Application Number:	13/060,225
Patent Claims:	1. A manufactured pre-mixed formulation for injection comprising a suspension of (i) a pharmaceutically acceptable non-aqueous carrier comprising one or more triglycerides and (ii) microspheres which comprise a biocompatible, biodegradable polymer and an active pharmaceutical ingredient, and wherein the pharmaceutically acceptable non-aqueous carrier comprises from 0 to 2 wt % of C.sub.6 fatty acid, from 50 to 65 wt % of C.sub.8 fatty acid, from 30 to 45 wt % of C.sub.10 fatty acid, and form 0 to 2 wt % of C.sub.12 fatty acid based on the total fatty acid content of the one or more triglycerides. 2. The formulation of claim 1, further comprising a pharmaceutically acceptable excipient. 3. The formulation of claim 2, wherein the pharmaceutically acceptable excipient is a sugar, or a sugar alcohol, and the formulation further comprises an antioxidant, or a preservative, or a combination of two or more thereof. 4. The formulation of claim 2, wherein the pharmaceutically acceptable excipient is sucrose, glucose, dextrose, galactose, maltose, trehalose, fructose, maltodextrin, glycol, glycerol, erythritol, threitol, arabitol, ribitol, sorbitol, dulcitol, iditol, isomalt, maltitol, lactitol, mannitol, xylitol, benzoic acid, sorbic acid, meta cresol, sodium benzoate, potassium sorbate, methylparaben, propylparaben, butylparaben, benzalkonium chloride, sodium metabisulfite, butylated hydroxy anisole, butylated hydroxy toluene, sodium sulfite, tocopherol, thymol, ascorbate, propyl gallate, or a combination of two or more thereof. 5. The formulation of claim 1, wherein the formulation does not further comprise a gel-forming agent. 6. The formulation of claim 1, wherein the biocompatible, biodegradable polymer is a polylactide, a copolymer of a polylactide, a polyglycolide, a copolymer of a polyglycolide, a poly(lactide-co-glycolide) copolymer, a polylactic acid, a copolymer of a polylactic acid, a polyglycolic acid, a copolymer of a polyglycolic acid, a poly(lactic acid-co-glycolic acid) copolymer, a polycaprolactone, a copolymer of a polycaprolactone, a polycarbonate, a copolymer of a polycarbonate, a polyesteramide, a copolymer of a polyesteramide, a polyanhydride, a copolymer of a polyanhydride, a polyamino acid, a copolymer of a polyamino acid, a polyorthoester, a copolymer of a polyorthoester, a polycyanoacrylate, a copolymer of a polycyanoacrylate, a poly(p-dioxanone), a copolymer of a poly(p-dioxanone), a polyalkylene oxalate, a copolymer of a polyalkylene oxalate, a polyurethane, a copolymer of a polyurethane, or a combination of two or more thereof. 7. The formulation of claim 1, wherein the active pharmaceutical ingredient is a GLP-1 receptor agonist, GLP-1(7-37), GLP-1(7-36)-NH.sub.2, exenatide, pramlintide, davalintide, Val.sup.27-davalintide, metreleptin, insulin, glucagon agonist, glucagon antagonist, a chimera of a GLP-1 receptor agonist and a glucagon agonist, bovine serum albumin, sodium salicylate, salicylic acid, minocycline HCl, insulin, or a small molecule organic compound. 8. The formulation of claim 1, wherein the microspheres are present in the formulation at a concentration of from 10 mg/ml to 500 mg/ml or from 20 mg/ml to 200 mg/ml. 9. A method for treating diabetes, stimulating insulin release; lowering plasma glucagon; reducing food intake; reducing appetite; decreasing gastric motility; delaying gastric emptying; lowering plasma lipid levels; treating impaired glucose tolerance; treating hyperglycemia; treating obesity; treating overweight; treating fatty liver disease; or treating non-alcoholic steatohepatitis in a patient in need thereof comprising administering to the patient the formulation of claim 1. 10. The method of claim 9, further comprising administering to the patient metformin, a sulfonylurea, a thiazolidinedione, or a combination of two or more thereof. 11. A kit comprising a container which comprises the formulation of claim 1 and instructions for use. 12. The kit of claim 11, wherein the container is a single-dose or multi-dose pen injector, single-dose or multi-dose vial, or single-dose or multi-dose cartridge. 13. A manufactured pre-mixed formulation for injection comprising a suspension of: (i) a pharmaceutically acceptable non-aqueous carrier comprising one or more triglycerides, wherein the carrier comprises from 0 to 2 wt % of C.sub.6 fatty acid, from 50 to 65 wt % of C.sub.8 fatty acid, from 30 to 45 wt % of C.sub.10 fatty acid, and from 0 to 2 wt % of C.sub.12 fatty acid based on the total fatty acid content of the one or more triglycerides; and (ii) microspheres comprising a poly(lactide-co-glycolide) polymer, about 2 wt % of sucrose; and about 5 wt % of exenatide as the active pharmaceutical ingredient, and wherein the ratio of lactide:glycolide in the polymer is about 1:1. 14. The manufactured pre-mixed formulation for injection of claim 6, wherein the biocompatible, biodegradable polymer is the poly(lactide-co-glycolide) polymer, wherein the ratio of lactide:glycolide in the polymer is about 1:1. 15. The manufactured pre-mixed formulation for injection of claim 7, wherein the active pharmaceutical ingredient is exenatide. 16. The manufactured pre-mixed formulation for injection of claim 15, wherein the exenatide is present in the microspheres in an amount of about 5 wt %. 17. The manufactured pre-mixed formulation for injection of claim 4, wherein the pharmaceutically acceptable excipient is sucrose. 18. The manufactured pre-mixed formulation for injection of claim 2, wherein the pharmaceutically acceptable excipient is sucrose; the biocompatible, biodegradable polymer is a poly(lactide-co-glycolide) polymer; the active pharmaceutical ingredient is exenatide.

Details for Patent 8,895,033

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amryt Pharmaceuticals Dac	MYALEPT	metreleptin	For Injection	125390	02/24/2014		2039-02-26